MediciNova's NAFLD Drug Trial Completes Patient Visits; Top-Line Data Expected Q3
MNOV sits 19% above its 52-week low of $1.168.
Summary
MediciNova announced the completion of the last patient last visit (LPLV) in its Phase 2 clinical trial for MN-001 (tipelukast), targeting hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes. This marks a significant operational milestone, moving the trial into the data analysis phase. For a clinical-stage biopharmaceutical company, successful progression through trials is crucial. Top-line data from this trial are expected in the third quarter of 2026.
At the time of this announcement, MNOV was trading at $1.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.4M. The 52-week trading range was $1.17 to $1.96. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.